Federal Xarelto Litigation Revving Up in Louisiana

Published on December 23, 2014 by Sandy Liebhard

Text-Size:A A A+

 

What could eventually become a massive litigation for federally-filed Xarelto lawsuits is beginning to move forward in Louisiana federal court. According to court documents, the U.S. District Judge overseeing the new Xarelto multidistrict litigation in the Eastern District of Louisiana has issued an Initial Case Management Order and scheduled the proceeding’s first conference.

The new litigation was established on December 11th by the U.S. Judicial Panel on Multidistrict Litigation, which initially transferred 21 federal claims filed on behalf of alleged victims of Xarelto bleeding to the Eastern District of Louisiana. The formation of a multidistrict litigation means that all Xarelto cases currently pending in federal courts, as well as those filed in the future, will be subjected to coordinated pretrial proceedings, including discovery and motions practice. This process not only conserves the resources of the Court and the parties, but it also eliminates duplicative discovery and inconsistent court rulings across a large number of similar claims.

According to an Initial Case Management Order issued in the Eastern District of Louisiana on December 17th, Xarelto lawyers representing both plaintiffs and defendants have been directed to provide the Court with statements detailing the questions and facts at issue in the litigation no later than January 20th. Among other things, the Order also outlines how the Court will go about appointing attorney to leadership positions in the proceeding.

Finally, the Order indicates that the Court will convene its first Case Management Conference on January 29, 2015. The meeting will begin at 1:00 a.m.

Xarelto Allegations

Xarelto is one of a new generation of blood thinners that was supposed to be an improvement over warfarin, a drug that has been on the market for decades. Like any anticoagulant, Xarelto can cause some patients to experience serious episode of internal hemorrhaging. However, there is currently no approved antidote to reverse Xarelto bleeding. Warfarin bleeding, by contrast, can be stopped via the administration of vitamin K.

The fact that there is no antidote for internal bleeding has prompted Xarelto lawsuit plaintiffs to dispute claims of its superiority over warfarin. They also allege that the drug’s manufacturers were wrong to assert that patients treated with Xarelto do not require regular blood monitoring.

The Xarelto lawyers at Bernstein Liebhard LLP are actively filing claims on behalf of individuals who allegedly experienced uncontrollable internal bleeding, strokes, blood clots and other problems that may be related to its use. If you suffered one of these Xarelto complications, please contact our Firm atto learn more about your legal options.

Web Analytics